Publication of 2022 EORTC Annual Report

This comprehensive report collects the most relevant and up-to-date information on EORTC’s activities demonstrating the continuous progress achieved in the field of clinical cancer research by our organisation.

The 2022 edition is a very special one, as last year marked a significant milestone for our organisation which celebrated its 60th anniversary. Today, EORTC is a well-renowned independent, academic and multidisciplinary clinical cancer research organisation, whose network encompasses over 3,400 collaborators from diverse disciplines across more than 50 countries. 22,000 patients continue to be followed on a yearly basis and the EORTC clinical study database now contains outcome data for over 210,000 cancer patients.

As well, EORTC contributes actively to the evolving eco-systems in oncology whether addressing methodological, scientific or regulatory challenges. EORTC remains also very active in education for clinical research-related science.

This year we celebrate our past, but we also recognise the importance of continually evolving and adapting to meet future challenges and keep building on our distinguished record of scientific achievements.
– Dr. Denis Lacombe, EORTC CEO.

On behalf of EORTC, we would like to express our sincere gratitude to all the people who support, collaborate, and believe in the mission of EORTC to improve the survival and quality of life of cancer patients. 

Back to news list

Related News

  • EORTC strategic meeting with Middle Eastern Ambassadors

  • EORTC Quality of Life Group projects to be presented at ISOQOL 2023

  • Celebrating Sarcoma Awareness Month with the start of EU-funded STREXIT 2 project study

  • “Best Proposal in Medicine” award received by EORTC at the PTCOG 61 Conference

  • Long-term efficacy and safety outcomes of the EORTC/LYSA/FIL H10 trial assessing early PET-scan adapted treatment of limited stage Hodgkin lymphoma

  • Joint Statement: health organisations define EHDS’ opt out required for life saving research

  • Congratulations to Dr. Hans Wildiers, winner of the B.J. Kennedy Geriatric Oncology Award

  • Full validation of the EORTC CAT Core

  • SISAQOL-IMI: Setting standards for the use of patient-reported outcome data in cancer trials

  • Synthesis of minimally important differences for interpreting EORTC QLQ-C30 change scores across nine cancer types